ANGIOTENSIN II RECEPTOR BLOCKADE IN THE PREVENTION OF INTERSTITIAL EXPANSION

血管紧张素 II 受体阻断预防间质扩张

• 批准号: 7375866
• 负责人: HASSAN N IBRAHIM
• 金额: $ 3.95万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375866
• 关键词: ANGIOTENSIN; II; RECEPTOR; BLOCKADE; PREVENTION

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The renin angiotensin aldosterone system (RAAS) plays an important role in the progression of renal diseases. Blockade of this system has yielded beneficial results in retarding injury and progression in numerous intrinsic renal diseases. This system, as well as other common mechanisms of progression, operate in chronic allograft nephropathy (CAN). This project will investigate the role of the renin angiotensin aldosterone system (RAAS) in the development of chronic renal allograft nephropathy (CAN). The specific aim is to perform a 5 year randomized placebo controlled primary prevention trial in 150 patients to determine if the angiotensin II receptor blocker, Losartan, can slow or prevent corticol interstitial volume expansion and graft loss from CAN in kidney transplant recipients. The proposed study should provide both pathophysiologic rational and a practical test of therapy in a disease for which there are presently few treatment options. Participants will be admitted to the GCRC for their 5 year exit biopsy.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。肾素血管紧张素醛固酮系统（RAAS）在肾脏疾病的进展中起重要作用。阻断该系统已产生有益的结果，延缓损伤和进展在许多内在肾脏疾病。这个系统，以及其他常见的进展机制，在慢性同种异体肾病（CAN）中起作用。本项目将探讨肾素血管紧张素醛固酮系统（RAAS）在慢性同种异体肾移植肾病（CAN）发展中的作用。具体目的是在150例患者中进行一项为期5年的随机安慰剂对照一级预防试验，以确定血管紧张素II受体阻滞剂氯沙坦是否可以减缓或预防肾移植受者can引起的皮质间质体积扩张和移植物损失。提出的研究应提供病理生理理性和治疗的实际测试的疾病，目前有很少的治疗方案。参与者将进入GCRC进行5年的退出活检。